跳至主要内容
临床试验/JPRN-UMIN000016205
JPRN-UMIN000016205已完成未知

Effectiveness of simeprevir-based triple therapy for patients with telaprevir failure - Effectiveness of simeprevir for patients with telaprevir failure

The Kyushu Univerisity Liver Disease Study Group0 个研究点目标入组 30 人开始时间: 2015年1月13日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 90years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen 2. Clinical or biochemical evidence of hepatic decompensation (Child-Pugh B or C, ascites, bleeding varices, or encephalopathy); 3. Other causes of liver disease (hemochromatosis, autoimmune hepatitis, or primary biliary cirrhosis) 4. Excessive active alcohol consumption (a daily intake of more than 40g of ethanol), drug abuse or severe mental disorder 5. The presence of active cancer at entry

研究者

发起方
The Kyushu Univerisity Liver Disease Study Group

相似试验

Effectiveness of simeprevir-based triple therapy for... | 临床试验